OncoMatch/Clinical Trials/NCT05511623
Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer
Is NCT05511623 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies tislelizumab for cervical cancer.
Treatment: tislelizumab — To evaluate the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in first-line treatment of stage IIIC2 cervical cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIIC2
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Previously treatment with PD-1 and/or PD-L1, or CTLA-4 antibody, or other medications targeting immunomodulatory receptors
Lab requirements
Blood counts
hemoglobin ≥90g/L, neutrophils ≥1.5×10^9/L, platelets ≥80×10^9/L
Kidney function
Creatinine clearance ≥60 mL/min
Liver function
Total bilirubin ≤1.5 x institutional upper limit of normal, AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal, ALB≥30g/L
Participants must have normal organ and marrow function as defined below: (hemoglobin ≥90g/L, neutrophils ≥1.5×10^9/L, platelets ≥80×10^9/L, ALB≥30g/L, Total bilirubin≤1.5 x institutional upper limit of normal, AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal, Creatinine clearance≥60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify